U.S. Markets close in 3 hrs 8 mins

Biocon Limited (BIOCON.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
355.30-8.85 (-2.43%)
At close: 3:30PM IST
Full screen
Previous Close364.15
Bid0.00 x 0
Ask355.30 x 0
Day's Range353.60 - 363.60
52 Week Range268.13 - 438.85
Avg. Volume2,988,715
Market Cap208.7B
PE Ratio (TTM)40.03
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters3 months ago

    FDA rejects Coherus's biosimilar for Neulasta, shares plunge

    Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its biosimilar copy of Amgen Inc's blockbuster treatment, Neulasta, which is used to fight infections in cancer patients. Shares of Coherus tumbled 30 percent to $14.47 in morning trading, while Amgen's shares were up slightly at $164.19.

  • Reuters5 months ago

    India watchdog orders antitrust probe into Roche cancer drug

    India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original. India's Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.

  • Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
    Zacks7 months ago

    Mylan's Proposed Biosimailar for Cancer Under Review in U.S.

    Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.